生长抑素联合内镜下治疗肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究*

doi:10.3969/j.issn.1672-5069.2025.01.027

Abstract

Abstract: Objective The aim of this study was to investigate clinical efficacy of endoscopic tissue gel injection (ETGI) and endoscopic variceal ligation (EVL) in treatment of cirrhotics with esophagogastric variceal bleeding (EVB). Methods 89 patients with liver cirrhosis (LC) and complicated EVB were encountered in our hospital between January 2017 and November 2023, and were divided into control (n=45) and observation group (n=44). All patients were well treated by internal comprehensive supporting measurement, including hemostasis, blood transfusion and intravenous somatostatin administration, and patients in the observation group received ETGI and/or EVL at base of supporting treatment. Portal vein diameter (PVD), portal vein velocity (PVV) and splenic vein velocity (SVV) were detected by ultrasonography, and serum lipid peroxide (LPO), motilin (MTL) and gastrin (GAS) levels were assayed by ELISA. Results Successful hemostasis rate in the observation group was 97.7%, much higher than 88.9%(P<0.05) in the control; blood transfusion was (1.8±0.4)u, much less than [(4.2±2.0)u, P<0.05], hemostasis time was (0.8±0.2) day, much shorter than [(3.1±1.1)day, P<0.05] in the control, and disappearance of EV at re-gastroscopy in 9 cases (20.9%) in the observation group; there were no significant differences as respect to PVD, PVV and SVV in the two groups (P>0.05); after treatment, serum LPO, MTL and GAS levels in the observation group were (4.3±1.1)U/L, (193.6±20.4)ng/L and (85.5±9.2)μg/mL, all much lower than [(7.1±1.6)U/L, (254.9±24.9)ng/L and (112.4±10.3)μg/mL, respectively, P<0.05] in the control; by end of six-month follow-up, re-bleeding was found in 3 cases (7.0%) in the observation group, and they recovered after ETGI and/or EVL, while re-bleeding occurred in 17 cases (42.5%, P<0.05) in the control, and 5 (29.4%)of them died. Conclusion ETGI and/or EVL at supporting measures in dealing with emergent patients with EVB is efficacious in saving patient’s lives, which might be carried out by qualified clinicians.

Key words: Liver cirrhosis, Esophagogastric variceal bleeding, Endoscopic tissue gel injection, Endoscopic variceal ligation, Somatostatin, Therapy

Zhu Ruinong, Song Liqun, Qian Ji. Endoscopic tissue gel injection and endoscopic variceal ligation in treatment of cirrhotics with esophagogastric variceal bleeding[J]. Journal of Practical Hepatology, 2025, 28(1): 104-107.

References

[1] De Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol, 2022, 76(4): 959-974.
[2] Jakab SS, Garcia-Tsao G. Evaluation and management of esophageal and gastric varices in patients with cirrhosis. Clin Liver Dis, 2020, 24(3): 335-350.
[3] Zuckerman MJ, Elhanafi S, Mendoza Ladd A. Endoscopic treatment of esophageal varices. Clin Liver Dis, 2022, 26(1): 21-37.
[4] Simonnot M, Deprez PH, Pioche M,et al. Endoscopic resection of early esophageal tumors in patients with cirrhosis or portal hypertension: a multicenter observational study. Endoscopy, 2023, 55(9): 785-795.
[5] Bunchorntavakul C, Reddy KR. Pharmacologic management of portal hypertension. Clin Liver Dis, 2019, 23(4): 713-736.
[6] 中华医学会外科学分会脾及门静脉高压外科学组. 肝硬化门静脉高压症食管、胃底静脉曲张破裂出血诊治专家共识(2019年版). 中华外科杂志, 2019, 57(12): 885-892.
[7] Yoshitomi K, Hayashi T, Oe S,et al. Child-Pugh grade deterioration stratified by the etiology after transcatheter arterial chemoembolization as initial treatment for hepatocellular carcinoma. Sci Rep, 2024, 14(1): 3707.
[8] Gralnek IM, Camus Duboc M, Garcia-Pagan JC,et al. Endoscopic diagnosis and management of esophagogastric variceal hemorrhage: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy, 2022, 54(11): 1094-1120.
[9] Park MK, Lee YB. Diagnosis and management of esophageal and gastric variceal bleeding: Focused on 2019 KASL Clinical Practice Guidelines for liver cirrhosis. Korean J Gastroenterol, 2021, 78(3): 152-160.
[10] 涂建军,方翔,蒋琪,等. 乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者再出血影响因素及预测模型的建立. 实用肝脏病杂志, 2023, 26(5): 686-689.
[11] Liu B, Li G. Progress in endoscopic and interventional treatment of esophagogastric variceal bleeding. Dis Mark, 2022, 2022(1): 2940578.
[12] 戴欢,李凯,朱永湘,等. 内镜下套扎和注射硬化剂治疗乙型肝炎肝硬化并发食管胃底静脉曲张破裂出血患者疗效研究. 实用肝脏病杂志, 2023, 26(1): 87-90.
[13] Sekiguchi H, Yano T, Tokoro S,et al. Low-pressure endoscopy using the gel immersion method facilitates endoscopic variceal ligation of ruptured esophageal varices. Endoscopy, 2022, 54(8): 828-829.
[14] Yang Z, Wang Y, Yu Q,et al. Efficacy of endoscopic intervention plus growth inhibitor and patient self-management in the treatment of esophagogastric variceal bleeding in cirrhosis. Evid Based Complement Alternat Med, 2022, 2022(1): 6837791.
[15] Zhang ZL, Peng MS, Chen ZM,et al. Effect of aluminum phosphate gel on prevention of early rebleeding after ligation of esophageal variceal hemorrhage. World J Gastrointest Surg,2021, 13(12): 1651-1659.
[16] Yao H, Wang Y. Relationship between hemodynamic parameters and portal venous pressure in cirrhosis patients with portal hypertension. Open Life Sci, 2020, 15(1): 981-987.
[17] Cheikhna FZ, Elgasmi N, Tahiri M,et al. Gastrointestinal bleeding due to the expulsion of cyanoacrylate glue after endoscopic embolization of gastric varices: a case report. Pan Afr Med J, 2022, 43(1): 75.
[18] Troisi RI, Vanlander A, Giglio MC,et al. Somatostatin as inflow modulator in liver-transplant recipients with severe portal hypertension: A randomized trial. Ann Surg, 2019, 269(6): 1025-1033.
[19] Wu W, Xiang Y, Zhang F,et al. Balloon-compression endoscopic injection sclerotherapy for the treatment of esophageal varices. Video GIE, 2021, 7(1): 23-25.
[20] 肖潇,盛云建. 内镜下曲张静脉套扎术联合经颈静脉肝内门体静脉分流术治疗肝硬化食管胃底静脉曲张破裂出血患者效果研究. 实用肝脏病杂志, 2024,27(2): 238-241.

Endoscopic tissue gel injection and endoscopic variceal ligation in treatment of cirrhotics with esophagogastric variceal bleeding

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Wang Fei, Liu Yingbin, Zhao Yuanyuan. Antiviral efficacy of pegylated interferon α-2a and albavir/granrivir combination in the treatment of patients with chronic hepatitis C [J]. Journal of Practical Hepatology, 2025, 28(1): 40-43.
[2]	Shen Lili, Zhao Lin, Shi Lei. Prevalence of third-generation cephalosporin resistance in patients with decompensated hepatitis B cirrhosis and spontaneous bacterial peritonitis [J]. Journal of Practical Hepatology, 2025, 28(1): 88-91.
[3]	Yang Huiling, Zhao Wenzhe, Yang Liuqing, et al. DCE-MRI functional imaging parameters in the diagnosis of decompensated liver functions in patients with hepatitis B-related liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 92-95.
[4]	Ye Peng, Yang Benchang, Mao Ming. Long-term observation of entecavir treatment for histological improvement in patients with compensated hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 96-99.
[5]	Si Tong, Zhu Jiabao, Wu Binbin. Ultrasonography and shear wave elastography in predicting high risk esophageal varices in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 100-103.
[6]	Zhuo Yuhong, Chen Pinghu, Chen Hongcheng, et al. Oral maintaining treatment of propranolol after endoscopic variceal ligation and somatostatin combination for emergent hemostasis in patients with esophagogastric variceal bleeding [J]. Journal of Practical Hepatology, 2025, 28(1): 108-111.
[7]	Wang Xuli, Cai Mingyue, Zhou Zhiming, et al. CT-measured liver volume in patients with hepatitis B-induced liver cirrhosis with different Child-Pugh class [J]. Journal of Practical Hepatology, 2025, 28(1): 112-115.
[8]	Xu Wenhui, Xu Jingyun, Li Binbin, et al. Comparison of indirect calorimetry and Harris-Benedict formulain measuring resting energy expenditure in patients with decompensated hepatitis B-induced liver cirrhosis [J]. Journal of Practical Hepatology, 2025, 28(1): 116-119.
[9]	Wang Wendong, Liang Maoquan, Liu Yuyan. Portal vein hemodynamic changes in patients with liver cirrhosis and portal hypertension after transjugular intrahepatic portal shunting and partial splenic artery embolization [J]. Journal of Practical Hepatology, 2025, 28(1): 120-123.
[10]	Zhang Shaobo, Zhang Shugeng, Liu Lianxin. Immunotherapy in hepatocellular carcinoma patients after liver transplantation:Current knowledge and future perspectives [J]. Journal of Practical Hepatology, 2024, 27(6): 801-803.
[11]	Zheng Hao, Zhang Shugeng, Wang Jiabei, et al. Therapeutic strategies for patients with recurrent hepatocellular carcinoma after liver transplantation [J]. Journal of Practical Hepatology, 2024, 27(6): 804-807.
[12]	Zhu Zebin, Zhang Shugeng, Liu Lianxin. Targeted therapy and immunotherapy in downstaging of patients with hepatocellular carcinoma before liver transplantation [J]. Journal of Practical Hepatology, 2024, 27(6): 808-811.
[13]	Zhang Tianting, Xu Jing, Jiang Zhengwei, et al. Improvement of liver fibrosis in patients with chronic hepatitis B after tenofovir alafenamide fumarate antiviral and herbal medicine anti-fibrotic therapy [J]. Journal of Practical Hepatology, 2024, 27(6): 820-823.
[14]	Zhang Li, Feng Xixuan, Liu Fei, et al. Combination of tenofovir alafenamide and PEG-IFNα-2b in treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2024, 27(6): 824-827.
[15]	Zhu Zhonghua, Hu Junxian, Li Yan. Serumv on Willebrand factor and soluble vascular cell adhesion molecule-1 level changes in patients with hepatitis C viral infection [J]. Journal of Practical Hepatology, 2024, 27(6): 836-839.